4//SEC Filing
Edwards Lifesciences Corp 4
Accession 0001225208-17-008604
$EWCIK 0001099800operating
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 5:10 PM ET
Size
13.1 KB
Accession
0001225208-17-008604
Insider Transaction Report
Form 4
Verguet Patrick B
CVP, Europe
Transactions
- Sale
Common Stock
2017-04-27$108.36/sh−6,705$726,523→ 146,432.15 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2017-04-27−24,000→ 0 totalExercise: $25.48From: 2011-05-13Exp: 2017-05-12→ Common Stock (24,000 underlying) - Exercise/Conversion
Common Stock
2017-04-27$25.48/sh+24,000$611,520→ 153,137.15 total - Sale
Common Stock
2017-04-27$109.33/sh−9,659$1,055,988→ 129,137.15 total - Sale
Common Stock
2017-04-27$110.08/sh−7,636$840,580→ 138,796.15 total
Footnotes (6)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017.
- [F2]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
- [F3]This transaction was executed in multiple trades at prices ranging from $107.83 to $108.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $109.89 to $110.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $108.83 to $109.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001099800
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 5:10 PM ET
- Size
- 13.1 KB